Postoperative recurrence (POR) remains a significant challenge in Crohn’s disease (CD) management despite therapeutic advances. Contemporary data show ileocecal resection rates of 18.7%, 28.0%, and 39.5% at one, five, and ten years after diagnosis, with endoscopic recurrence occurring in 22.4–53% of patients within 18–36 months postoperatively. Current understanding of POR pathophysiology includes microbiota dysbiosis, mesenteric inflammation, immune dysregulation, and genetic factors, particularly NOD2 variants. Key risk factors comprehend smoking, penetrating or perianal disease, prior surgeries, and extensive small bowel involvement. The Rutgeerts score remains the endoscopic gold standard for assessing recurrence, though it has never been validated and modifications addressing modern anastomotic techniques have been proposed. Non-invasive monitoring strategies using fecal calprotectin, intestinal ultrasound, and magnetic resonance enterography demonstrate promising diagnostic performance and may reduce the burden of routine endoscopy. Anti-TNF agents and Vedolizumab show superior efficacy in preventing endoscopic recurrence compared to conventional therapies, while other advanced therapies like anti-JAKs, risankizumab and ustekinumab demonstrate potential benefit in postoperative prophylaxis. Management approaches have evolved toward risk-stratified strategies balancing systematic prophylaxis against endoscopy-driven therapy. While medical prophylaxis remains first-line for high-risk patients, the expanding therapeutic armamentarium and improved understanding of pathophysiologic mechanisms enable increasingly personalized postoperative care. Further research is needed to validate risk assessment tools, optimize timing and selection of prophylactic therapies, and define the role of emerging agents in reducing long-term disease burden.
Primary intestinal lymphangiectasia (PIL; Waldmann’s disease, ORPHA 90362) is a rare protein-losing enteropathy in which dilated intestinal lacteals leak chyle into the gut lumen. Cross-sectional imaging and lymphoscintigraphy have historically dominated assessment, while transabdominal B-mode intestinal ultrasound (IUS)—a cornerstone modality for inflammatory bowel disease—has remained almost unmapped in PIL. We conducted a PRISMA-ScR scoping review (Open Science Framework preregistration gfbc9) of all primary studies reporting transabdominal B-mode IUS in PIL, searching three bibliographic platforms (PubMed/MEDLINE, Ovid Multifile, Scopus) supplemented by forward and backward citation chasing. Studies using only extra-intestinal ultrasound, endoscopic ultrasound, those describing secondary lymphangiectasia or focal lymphangioma, and those using ultrasound only as procedural guidance for lymphangiography were excluded at full-text stage. Fifteen primary studies, published 1986–2026 across thirteen countries, met eligibility (nine paediatric, six adult). All fifteen reported per-patient B-mode IUS findings extractable for synthesis. A consistent sonographic signature emerged: diffuse, regular, slightly hypoechoic small-bowel-wall thickening with preserved five-layer stratification and prominent valvulae conniventes; dilated fluid-filled loops with reduced peristalsis; oedematous mesentery, variable ascites; and characteristically absent mesenteric lymphadenopathy (with two notable exceptions framed only as a research hypothesis). Diagnostic accuracy as a screening tool has been evaluated only in one study ( n = 20: accuracy 80%, 95% CI 56.3–94.3%). We illustrate this signature in a 42-year-old woman with Hennekam syndrome and report quantitative B-mode IUS values as anecdotal single-observation—single sonographer, single device, single fasted time-point, mid-jejunal segment to motivate, prospective standardisation.